CHMP nod for Novartis's Jakavi
This article was originally published in Scrip
Executive Summary
The EU's CHMP has granted a positive opinion to Novartis's oral JAK inhibitor Jakavi (ruxolitinib; licensed from Incyte) for the treatment of patients with myelofibrosis.